ClinicalTrials.Veeva

Menu
P

PRX Research | Mesquite, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

AVP-786
Deudextromethorphan Hydrobromide
Retatrutide
Dapagliflozin
Amlitelimab
SAR440340
GT0918
Proxalutamide
Lorundrostat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 11 total trials

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.The purpo...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Amlitelimab

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Enrolling
Chronic Kidney Disease
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), Exo...

Enrolling
Acute Respiratory Distress Syndrome
ARDS
Other: Intravenous normal saline
Biological: ExoFlo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Active, not recruiting
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

D
Lilly logo
Otsuka logo
Sanofi logo
G
K
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems